Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.73
RHHBY's Cash to Debt is ranked higher than
56% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. RHHBY: 0.73 )
RHHBY' s 10-Year Cash to Debt Range
Min: 0.39   Max: No Debt
Current: 0.73

Equity to Asset 0.34
RHHBY's Equity to Asset is ranked lower than
51% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. RHHBY: 0.34 )
RHHBY' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.59
Current: 0.34

0.1
0.59
F-Score: 7
Z-Score: 5.03
M-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 35.01
RHHBY's Operating margin (%) is ranked higher than
98% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.93 vs. RHHBY: 35.01 )
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.53   Max: 35.01
Current: 35.01

4.53
35.01
Net-margin (%) 23.86
RHHBY's Net-margin (%) is ranked higher than
96% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. RHHBY: 23.86 )
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.67   Max: 30.16
Current: 23.86

-13.67
30.16
ROE (%) 52.56
RHHBY's ROE (%) is ranked higher than
99% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. RHHBY: 52.56 )
RHHBY' s 10-Year ROE (%) Range
Min: -19.35   Max: 105.67
Current: 52.56

-19.35
105.67
ROA (%) 17.96
RHHBY's ROA (%) is ranked higher than
98% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. RHHBY: 17.96 )
RHHBY' s 10-Year ROA (%) Range
Min: -6.29   Max: 17.96
Current: 17.96

-6.29
17.96
ROC (Joel Greenblatt) (%) 95.05
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.90 vs. RHHBY: 95.05 )
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.62   Max: 95.05
Current: 95.05

8.62
95.05
EPS Growth (%) 8.60
RHHBY's EPS Growth (%) is ranked higher than
74% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. RHHBY: 8.60 )
RHHBY' s 10-Year EPS Growth (%) Range
Min: -3.8   Max: 341.1
Current: 8.6

-3.8
341.1
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

RHHBY Guru Trades in Q2 2013

Ken Fisher 905,902 sh (+0.9%)
Tweedy Browne Sold Out
» More
Q3 2013

RHHBY Guru Trades in Q3 2013

Bill Frels 610,205 sh (New)
Ken Fisher 908,434 sh (+0.28%)
» More
Q4 2013

RHHBY Guru Trades in Q4 2013

Bill Frels 1,013,940 sh (+66.16%)
Ken Fisher 906,056 sh (-0.26%)
» More
Q1 2014

RHHBY Guru Trades in Q1 2014

Ken Fisher 1,803,070 sh (+99%)
Bill Frels 2,138,396 sh (+5.45%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Tweedy Browne 2013-06-30 Sold Out $28.92 - $32.98 $ 36.8319%0
Tweedy Browne 2012-09-30 Reduce -24.31%0.03%$20.95 - $24.07 $ 36.8364%62164
Vanguard Health Care Fund 2012-06-30 Add 543.36%2.96%$19.47 - $23.14 $ 36.8374%4273977
Tweedy Browne 2012-03-31 Reduce -22.19%0.04%$21.55 - $22.17 $ 36.8384%82130
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.20
RHHBY's P/E(ttm) is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.50 vs. RHHBY: 20.20 )
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.29   Max: 53.68
Current: 20.2

13.29
53.68
P/B 10.50
RHHBY's P/B is ranked higher than
50% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. RHHBY: 10.50 )
RHHBY' s 10-Year P/B Range
Min: 2.64   Max: 22.21
Current: 10.5

2.64
22.21
P/S 4.87
RHHBY's P/S is ranked higher than
65% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. RHHBY: 4.87 )
RHHBY' s 10-Year P/S Range
Min: 2.21   Max: 6.45
Current: 4.87

2.21
6.45
PFCF 17.40
RHHBY's PFCF is ranked higher than
93% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 17.40 )
RHHBY' s 10-Year PFCF Range
Min: 8.19   Max: 39.65
Current: 17.4

8.19
39.65
EV-to-EBIT 14.03
RHHBY's EV-to-EBIT is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.97 vs. RHHBY: 14.03 )
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 32
Current: 14.03

7.9
32
PEG 5.10
RHHBY's PEG is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 356.67 vs. RHHBY: 5.10 )
RHHBY' s 10-Year PEG Range
Min: 0.27   Max: 5.1
Current: 5.1

0.27
5.1
Shiller P/E 23.30
RHHBY's Shiller P/E is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 23.30 )
RHHBY' s 10-Year Shiller P/E Range
Min: 13.87   Max: 109.8
Current: 23.3

13.87
109.8
Current Ratio 1.85
RHHBY's Current Ratio is ranked higher than
64% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. RHHBY: 1.85 )
RHHBY' s 10-Year Current Ratio Range
Min: 1.55   Max: 3.75
Current: 1.85

1.55
3.75
Quick Ratio 1.48
RHHBY's Quick Ratio is ranked higher than
66% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.67 vs. RHHBY: 1.48 )
RHHBY' s 10-Year Quick Ratio Range
Min: 1.28   Max: 3.22
Current: 1.48

1.28
3.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.02
RHHBY's Dividend Yield is ranked higher than
87% of the 452 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. RHHBY: 3.02 )
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74   Max: 3.79
Current: 3.02

0.74
3.79
Dividend Payout 0.56
RHHBY's Dividend Payout is ranked higher than
94% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 0.56 )
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.55
Current: 0.56

0.21
0.55
Dividend growth (3y) -7.30
RHHBY's Dividend growth (3y) is ranked higher than
69% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. RHHBY: -7.30 )
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: -7.3

0
27.3
Yield on cost (5-Year) 2.46
RHHBY's Yield on cost (5-Year) is ranked higher than
77% of the 459 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. RHHBY: 2.46 )
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 0.61   Max: 3.11
Current: 2.46

0.61
3.11
Share Buyback Rate -0.20
RHHBY's Share Buyback Rate is ranked higher than
81% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. RHHBY: -0.20 )
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 22.50
RHHBY's Price/Tangible Book is ranked higher than
54% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. RHHBY: 22.50 )
RHHBY' s 10-Year Price/Tangible Book Range
Min: 4.05   Max: 95.2
Current: 22.5

4.05
95.2
Price/DCF (Projected) 2.20
RHHBY's Price/DCF (Projected) is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 2.20 )
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.27   Max: 7.13
Current: 2.2

1.27
7.13
Price/Median PS Value 1.20
RHHBY's Price/Median PS Value is ranked higher than
70% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. RHHBY: 1.20 )
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.76   Max: 1.28
Current: 1.2

0.76
1.28
Price/Graham Number 4.50
RHHBY's Price/Graham Number is ranked higher than
70% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. RHHBY: 4.50 )
RHHBY' s 10-Year Price/Graham Number Range
Min: 1.78   Max: 7.97
Current: 4.5

1.78
7.97
Earnings Yield (Greenblatt) 7.10
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
83% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.00 vs. RHHBY: 7.10 )
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 12.7
Current: 7.1

3.1
12.7
Forward Rate of Return (Yacktman) 3.77
RHHBY's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. RHHBY: 3.77 )
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.2   Max: 146.2
Current: 3.77

4.2
146.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.country, 0QOK.country
Roche was founded in 1896 and is headquartered in Basel, Switzerland and is a pharmaceutical and diagnostics company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. Roche also participates in in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management. Genentech, in the United States, and Chugai Pharmaceuticals are subsidiaries of the Roche Group. The firm's business is segmented into the dharmaceuticals business and the diagnostics Business.
» More Articles for OTCPK:RHHBY

Headlines

Articles On GuruFocus.com
Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
Signature Select Canadian Fund's Top Holdings Jul 02 2014 
The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
Most Popular International Stocks of Investment Gurus Mar 05 2014 
John Rogers' Ariel Fund Comments on Roche Feb 28 2014 
Ariel International Fund & Ariel Global Fund - Healthy Ideas Feb 28 2014 
Tweedy Browne Global Value’s Top Five Year End Stocks Jan 24 2014 
Invesco European Growth Fund’s Top Five Jan 09 2014 
Vanguard Health Care Fund’s Top Third Quarter Holdings Oct 31 2013 
Tweedy Browne Global Value Fund’s Top Five Positions Oct 22 2013 


More From Other Websites
[$$] 9 Health Care Stocks From Index-Crushing Fund Jul 22 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer Jul 22 2014
Is Roche Eyeing Up A Bid For AstraZeneca plc? Jul 18 2014
Is Roche Eyeing Up A Bid For AstraZeneca plc? Jul 18 2014
Cepheid says Roche patent suit will not have material adverse impact on results Jul 17 2014
OTC Markets Group Announces Second Quarter Performance of OTCM ADR Index and OTCQX ADR 30 Index Jul 17 2014
Genentech Alzheimer's drug misses goals in studies Jul 16 2014
Genentech Alzheimer's drug misses goals in studies Jul 16 2014
Roche Gets Priority Review for Avastin Label Expansion Jul 16 2014
Roche Reports Mixed Results in Trial of an Alzheimer’s Drug Jul 16 2014
Genentech Avastin granted priority review by FDA Jul 15 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer Jul 15 2014
Roche Presents Encouraging Data on Cobimetinib Jul 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Steve.dunfield@google
ReplySteve.dunfield@google - 3 months ago
Adjust for split?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide